These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
470 related articles for article (PubMed ID: 22340095)
1. [Expression and significance of microRNAs in the p53 pathway in ovarian cancer cells and serous ovarian cancer tissues]. Zhang Q; He XJ; Ma LP; Li N; Yang J; Cheng YX; Cui H Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):885-90. PubMed ID: 22340095 [TBL] [Abstract][Full Text] [Related]
2. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Corney DC; Flesken-Nikitin A; Godwin AK; Wang W; Nikitin AY Cancer Res; 2007 Sep; 67(18):8433-8. PubMed ID: 17823410 [TBL] [Abstract][Full Text] [Related]
3. [miR-449b and miR-34c on inducing down-regulation of cell cycle-related proteins and cycle arrests in SKOV3-ipl cell, an ovarian cancer cell line]. Ma Lp; Li N; He Xj; Zhang Q Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Feb; 43(1):129-33. PubMed ID: 21321636 [TBL] [Abstract][Full Text] [Related]
4. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas]. Shao HL; Shen DH; Xue WC; Li Y; Yu YZ Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760 [TBL] [Abstract][Full Text] [Related]
5. Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube. Yang J; Zhou Y; Ng SK; Huang KC; Ni X; Choi PW; Hasselblatt K; Muto MG; Welch WR; Berkowitz RS; Ng SW BMC Cancer; 2017 Jun; 17(1):422. PubMed ID: 28623900 [TBL] [Abstract][Full Text] [Related]
6. Functional analysis of miR-34c as a putative tumor suppressor in high-grade serous ovarian cancer. Yu Z; Kim J; He L; Creighton CJ; Gunaratne PH; Hawkins SM; Matzuk MM Biol Reprod; 2014 Nov; 91(5):113. PubMed ID: 25273528 [TBL] [Abstract][Full Text] [Related]
7. MicroRNA-34a: a novel tumor suppressor in p53-mutant glioma cell line U251. Luan S; Sun L; Huang F Arch Med Res; 2010 Feb; 41(2):67-74. PubMed ID: 20470934 [TBL] [Abstract][Full Text] [Related]
8. Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers. Creighton CJ; Fountain MD; Yu Z; Nagaraja AK; Zhu H; Khan M; Olokpa E; Zariff A; Gunaratne PH; Matzuk MM; Anderson ML Cancer Res; 2010 Mar; 70(5):1906-15. PubMed ID: 20179198 [TBL] [Abstract][Full Text] [Related]
9. MicroRNA expression profiles in serous ovarian carcinoma. Nam EJ; Yoon H; Kim SW; Kim H; Kim YT; Kim JH; Kim JW; Kim S Clin Cancer Res; 2008 May; 14(9):2690-5. PubMed ID: 18451233 [TBL] [Abstract][Full Text] [Related]
10. [Potential role of ezrin and its related microRNA in ovarian cancer invasion and metastasis]. Li J; Liang SH; Lu X Zhonghua Fu Chan Ke Za Zhi; 2010 Oct; 45(10):787-92. PubMed ID: 21176563 [TBL] [Abstract][Full Text] [Related]
11. [Preliminary study on the relationship between tubal intraepithelial carcinoma of the fimbria and pelvic high-grade serous carcinoma]. Liang Y; Chen XD; Lü BJ; Zhou CY; Zhang XF; Shi HY Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):724-8. PubMed ID: 22321343 [TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma. Chiesa-Vottero AG; Malpica A; Deavers MT; Broaddus R; Nuovo GJ; Silva EG Int J Gynecol Pathol; 2007 Jul; 26(3):328-33. PubMed ID: 17581420 [TBL] [Abstract][Full Text] [Related]
13. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas. Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429 [TBL] [Abstract][Full Text] [Related]
14. Loss of p16INK4A expression in low-grade ovarian serous carcinomas. Schlosshauer PW; Deligdisch L; Penault-Llorca F; Fatemi D; Qiao R; Yao S; Pearl M; Yang Z; Sheng T; Dong J Int J Gynecol Pathol; 2011 Jan; 30(1):22-9. PubMed ID: 21131838 [TBL] [Abstract][Full Text] [Related]
15. [Clinicopathologic study and immunohistochemistry comparison of Pax2, p53 and Ki-67 in low- and high-grade ovarian serous carcinomas]. Shen XX; Yu L; Bi R; Yang WT Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):511-6. PubMed ID: 22169637 [TBL] [Abstract][Full Text] [Related]
17. [Screening and identification of potential miRNA involved in ovarian cancer invasion and metastasis]. Liang SH; Li J; Al-beit M; Zhang J; Ma D; Lu X Zhonghua Zhong Liu Za Zhi; 2010 Sep; 32(9):650-4. PubMed ID: 21122376 [TBL] [Abstract][Full Text] [Related]
18. p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary. Leonhardt K; Einenkel J; Sohr S; Engeland K; Horn LC Int J Gynecol Pathol; 2011 Sep; 30(5):417-24. PubMed ID: 21804388 [TBL] [Abstract][Full Text] [Related]
19. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma. Salvador S; Rempel A; Soslow RA; Gilks B; Huntsman D; Miller D Gynecol Oncol; 2008 Sep; 110(3):408-17. PubMed ID: 18597838 [TBL] [Abstract][Full Text] [Related]
20. Expression of Interactive Genes Associated with Apoptosis and Their Prognostic Value for Ovarian Serous Adenocarcinoma. Shin K; Kim KH; Yoon MS; Suh DS; Lee JY; Kim A; Eo W Adv Clin Exp Med; 2016; 25(3):513-21. PubMed ID: 27629740 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]